Conventionally, the brand new antibody leads were discovered by two or more screening cycles with bunch of materials and time. Our approaches (In-silico screening, ISS) will revolutionize the conventional processes of biologics discovery and development by increasing R&D productivity as well as reducing attrition rates of therapeutic antibodies against most diseases, such as cancers, metabolic disorders, infections and neuron degenerations. The target customers are big pharma, biotech or stakeholders. We help them to control the cost and facilitate the total product life cycle toward regulatory approval using our core technologies. Namely, our services and products shall enable R&D groups in identifying drug candidates with a higher probability of success.